S&P: The upgrade reflects Teva's leading position in the growing generic drug industry.
A "Thomson Financial" news report featured in "Forbes" today said that Standard & Poor's has raised its corporate credit and senior unsecured debt ratings on Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) to 'BBB+ with a stable outlook from 'BBB'.
S&P said the upgrade " reflected Teva's leading position in the growing generic drug industry, its continued expected solid operating performance, and disciplined financial policies that are consistent with its investment-grade ratings."
Published by Globes [online], Israel business news - www.globes-online.com - on March 18, 2008
© Copyright of Globes Publisher Itonut (1983) Ltd. 2008